Alluvi, known as BI 4744, offers a promising development in obesity therapy. This dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates remarkable efficacy in patient https://allyourbookmarks.com/story22175050/alluvi-a-in-depth-dive-into-retatrutide-s-prospects